Findings from a real world study in India patients confirms that montelukast, a leukotriene inhibitor that is used to prevent asthma attacks in adults and children, is the most preferred choice and its administration in 10mg/day does improve the clinical symptoms and effects of both asthma and allergic rhinitis. 

The study undertaken by Indian researcher Nikhil Sharma and team to analyse the quality of life among patients of allergic rhinitis has found that 86.5 percent of patients treated with montelukast had significant improvements in their daytime allergies and about 88.5% had improvement in their night-time symptoms of coughing, wheezing, shortness of breath etc.

The researchers said that they analysed data from 5,585 patients for 4-8 weeks to reach their conclusions.